Towards personalized therapy for patients with malignant melanoma: Molecular insights into the biology of BRAF mutations

Joshua R. Bradish, Rodolfo Montironi, Antonio Lopez-Beltran, Kristin M. Post, Gregory T. MacLennan, Liang Cheng

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

BRAF mutations have been identified as the most common oncogene mutation in melanomas, especially important in those originating on nonchronically sun-damaged skin. There is a large and continually growing body of evidence regarding the importance of this mutation in targeted therapy for melanoma. In this review, we outline these findings including: molecular pathways used by BRAF, the importance in nonmalignant neoplasms, histologic associations, the relationship of BRAF to KIT and NRAS mutations, and their impact on survival, as well as resistance mechanisms to BRAF inhibitors employed by melanoma. Understanding these topics and how they relate to one another may facilitate the development of new treatments and eventually improve the prognosis for those patients afflicted with this disease.

Original languageEnglish
Pages (from-to)245-253
Number of pages9
JournalFuture Oncology
Volume9
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Melanoma
Mutation
Solar System
Therapeutics
Oncogenes
Skin
Survival
Neoplasms

Keywords

  • BRAF mutation
  • KIT mutation
  • malignant melanoma
  • metastasis
  • NRAS mutation
  • pathway targeting
  • personalized medicine
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Towards personalized therapy for patients with malignant melanoma : Molecular insights into the biology of BRAF mutations. / Bradish, Joshua R.; Montironi, Rodolfo; Lopez-Beltran, Antonio; Post, Kristin M.; MacLennan, Gregory T.; Cheng, Liang.

In: Future Oncology, Vol. 9, No. 2, 02.2013, p. 245-253.

Research output: Contribution to journalArticle

Bradish, Joshua R. ; Montironi, Rodolfo ; Lopez-Beltran, Antonio ; Post, Kristin M. ; MacLennan, Gregory T. ; Cheng, Liang. / Towards personalized therapy for patients with malignant melanoma : Molecular insights into the biology of BRAF mutations. In: Future Oncology. 2013 ; Vol. 9, No. 2. pp. 245-253.
@article{1d308c636ed741218db3ad09748d27fa,
title = "Towards personalized therapy for patients with malignant melanoma: Molecular insights into the biology of BRAF mutations",
abstract = "BRAF mutations have been identified as the most common oncogene mutation in melanomas, especially important in those originating on nonchronically sun-damaged skin. There is a large and continually growing body of evidence regarding the importance of this mutation in targeted therapy for melanoma. In this review, we outline these findings including: molecular pathways used by BRAF, the importance in nonmalignant neoplasms, histologic associations, the relationship of BRAF to KIT and NRAS mutations, and their impact on survival, as well as resistance mechanisms to BRAF inhibitors employed by melanoma. Understanding these topics and how they relate to one another may facilitate the development of new treatments and eventually improve the prognosis for those patients afflicted with this disease.",
keywords = "BRAF mutation, KIT mutation, malignant melanoma, metastasis, NRAS mutation, pathway targeting, personalized medicine, targeted therapy",
author = "Bradish, {Joshua R.} and Rodolfo Montironi and Antonio Lopez-Beltran and Post, {Kristin M.} and MacLennan, {Gregory T.} and Liang Cheng",
year = "2013",
month = "2",
doi = "10.2217/fon.12.179",
language = "English",
volume = "9",
pages = "245--253",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Towards personalized therapy for patients with malignant melanoma

T2 - Molecular insights into the biology of BRAF mutations

AU - Bradish, Joshua R.

AU - Montironi, Rodolfo

AU - Lopez-Beltran, Antonio

AU - Post, Kristin M.

AU - MacLennan, Gregory T.

AU - Cheng, Liang

PY - 2013/2

Y1 - 2013/2

N2 - BRAF mutations have been identified as the most common oncogene mutation in melanomas, especially important in those originating on nonchronically sun-damaged skin. There is a large and continually growing body of evidence regarding the importance of this mutation in targeted therapy for melanoma. In this review, we outline these findings including: molecular pathways used by BRAF, the importance in nonmalignant neoplasms, histologic associations, the relationship of BRAF to KIT and NRAS mutations, and their impact on survival, as well as resistance mechanisms to BRAF inhibitors employed by melanoma. Understanding these topics and how they relate to one another may facilitate the development of new treatments and eventually improve the prognosis for those patients afflicted with this disease.

AB - BRAF mutations have been identified as the most common oncogene mutation in melanomas, especially important in those originating on nonchronically sun-damaged skin. There is a large and continually growing body of evidence regarding the importance of this mutation in targeted therapy for melanoma. In this review, we outline these findings including: molecular pathways used by BRAF, the importance in nonmalignant neoplasms, histologic associations, the relationship of BRAF to KIT and NRAS mutations, and their impact on survival, as well as resistance mechanisms to BRAF inhibitors employed by melanoma. Understanding these topics and how they relate to one another may facilitate the development of new treatments and eventually improve the prognosis for those patients afflicted with this disease.

KW - BRAF mutation

KW - KIT mutation

KW - malignant melanoma

KW - metastasis

KW - NRAS mutation

KW - pathway targeting

KW - personalized medicine

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84874028989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874028989&partnerID=8YFLogxK

U2 - 10.2217/fon.12.179

DO - 10.2217/fon.12.179

M3 - Article

C2 - 23414474

AN - SCOPUS:84874028989

VL - 9

SP - 245

EP - 253

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 2

ER -